Skip to main content
OpenTrials
Completed

NCT Number: NCT07455110

EORTC Quality of Life Measurement in Males With Breast Cancer

Around 1% of all new cases of breast cancer (BC) diagnosed annually occur in men. Most research to date has focused on female breast cancer (FBC). So what is known about breast cancer in men has been mostly derived from the research and treatment of FBC. Comprehensive, prospective data about Quality of life in men treated for BC is lacking. Therefore, a validated worldwide questionnaire for male BC will be developed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Helios University Clinic Wuppertal, University Witten/Herdecke

Wuppertal, North Rhine-Westphalia, 42283, Germany

About this study

One percent of all new cases of breast cancer (BC) diagnosed annually is male BC. Although, the incidence increased by about 26% over the past 25 years, basic and clinical research focusing on male BC is limited. Care of male breast cancer is largely based on extrapolation from treatment strategies and management of symptoms in women. Comprehensive, prospective data about QoL in men treated for BC are lacking. A few studies have focused on symptoms and two small studies have focused on QoL.

The evaluation of the QoL issues relevant for male BC, as well as the translation of issues into items to build the tool for QoL assessment in male BC will be carried through four phases: 1.Literature review: A systematic review with the question what factors are unique to male BC in influencing their QoL and what QoL measures exist for male BC will be done by review of all studies with male BC, investigator brochures (IB) of the describing side effects, review of the existing issues in other EORTC modules . 2. Interviews with patients: Interviews with patients will be undertaken to get information on the most relevant issues influencing QoL. The interviews can be held face-to-face or via telephone. The patient interviews are used to create a list of relevant and important issues which are already covered by the EORTC QLQ-C30, QLQ-BR45 and QLQ-PR25. A semi-structured interview will be carried out. In case of phone interviews, the study documents are handed out in advance so that the patient has the documents available during the interview. Patients will also be asked to rate the importance of each of the items ( 4-point Likert scale) , the appropriateness of the way the items are phrased and about options of alternative wording for items, which a priori are likely to be different for female BC or prostate patients with cancer. Additional issues will be documented carefully. 3.Interviews with health care professionals (HCP): HCP with special knowledge in the field will be interviewed to discuss and consider the potential issues (experts from the EORTC QLG, collaborating centres, EORTC Breast Group, as well as experts from the International Male BC Consortium Group). 4.Consultation of experts in Oncology and QoL: We will seek expert advice from experts in the field of treatment of male BC and in Qol assessment. The study proposes to gather all available evidence from the literature, as well as data from the qualitative interview and develop a succinct summary. Experts will be asked to comment on our findings and will also be asked specific questions around the necessity of the development of a new module, based on those findings and their expert views. These data will be collated and reported in the final report.

The study proposes to carry out an evaluation of the QoL issues relevant for male BC, and translating the issues in the items to build the tool for QoL assessment in male BC. The specific aims are:

  • To carry out an evaluation of the EORTC QLQ-BR 45 (adapting for male BC) and for suitability of use in male BC patients
  • To carry out an evaluation of the EORTC QLQ-PR25 (adapting for male BC) for suitability of use in male BC patients
  • To provide recommendations to the EC on a suitable assessment approach to assess HRQOL in male BC

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male sex
  • Evidence of invasive breast cancer (any type) and/or ductal carcinoma in situ (DCIS) (current or anamnestic).
  • Must be able and willing to complete the questionnaires.
  • Must be able to understand and speak the language in which the patient will complete the questionnaire.

Exclusion criteria

  • Cognitive impairment

Treatment and study plan

Structured Interview

Behavioral

Interviews with patients and health care professionals(HCP)

Primary outcomes

  1. Relevance

    Time frame: Single assessment at study enrollment (issues rated with recall period of the past 7 days or past 4 weeks, depending on item specification)

    Mean item relevance score (range 1-4; 1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much) on a study-specific issue list developed to identify quality of life issues in male breast cancer patients. Participants rate the extent to which they experienced each issue during the specified recall period (past 7 days or past 4 weeks, depending on item specification). Higher scores indicate greater perceived relevance of the issue.

  2. Importance

    Time frame: Single assessment at study enrollment

    Percentage of participants selecting each issue for inclusion in a male breast cancer-specific quality of life questionnaire. Participants are instructed to select approximately 25% (±5%) of issues (approximately 11-17 items) that they consider most important for assessing quality of life. Item selection frequency will be used to inform item retention decisions.

Sponsors and collaborators

Lead sponsor

Helios University Hospital Wuppertal

Other

Collaborators

  • East Kent Gynaecological Oncology Centre, Queen Elizabeth the Queen Mother Hospital
  • Medical University Innsbruck
  • Mugla Sitki Kocman University School of Medicine
  • Rigshospitalet, Denmark
  • Sorlandet Hospital HF
  • Sunnybrook Health Sciences Centre
  • UNED Pamplona
  • Unidad de cancer
  • University of Roma La Sapienza
  • University of Southern Denmark

Registry information

Official study title

Adaption of the EORTC Quality of Life Breast Cancer Module for Male Breast Cancer - Phase I

Acronym: BR Male

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Mar 6, 2026
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.